Biogen said total revenue for Q1 2026 rose 2% year over year to $2,478 million, GAAP diluted EPS was $2.15, and Non-GAAP diluted EPS was $3.57.

1. 01

   Biogen said total revenue for Q1 2026 rose 2% year over year to $2,478 million, GAAP diluted EPS was $2.15, and Non-GAAP diluted EPS was $3.57.

2. 02

   The company said it updated its full-year 2026 Non-GAAP diluted EPS outlook to $14.25 to $15.25 from the prior range of $15.25 to $16.25, reflecting an impact of about $1.00 from acquired IPR&D charges and excluding the Apellis transaction.

3. 03

   Biogen reported net cash flow from operations of $645.5 million for Q1 2026, purchases of property, plant and equipment of $51.2 million, and free cash flow of $594.3 million.

4. 04

   Biogen said it expects to close its acquisition of Apellis Pharmaceuticals in Q2 2026 and agreed with TJ Biopharma to acquire exclusive rights to felzartamab in the Greater China region.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.